Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hamid Nia

Internal Medicine Hackensack, NJ Medical Doctor

NPI 1073778429 CMS profile 49282

20 Prospect Ave Ste 615, Hackensack, NJ 07601

Open in the dashboard

General payments

$6,673

281 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hamid Nia of Hackensack, NJ is reported in the CMS Open Payments database as having received $6,673 across 281 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,066 31
2024 General $991 40
2023 General $957 47
2022 General $1,534 58
2021 General $1,088 50
2020 General $483 22
2019 General $553 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hamid Nia
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Hamid Nia were reported at $1,066. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Hamid Nia Internal Medicine median Middle half National median
2019 $553 $159 $48–$570 $163
2020 $483 $119 $33–$402 $114
2021 $1,088 $135 $37–$521 $132
2022 $1,534 $141 $42–$496 $149
2023 $957 $149 $45–$519 $160
2024 $991 $154 $47–$537 $164
2025 $1,066 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abiomed $1,561 38 payments
  2. Amgen Inc. $942 63 payments
  3. Novartis Pharmaceuticals Corporation $530 34 payments
  4. Merck Sharp & Dohme Corporation $395 26 payments
  5. AstraZeneca Pharmaceuticals LP $343 25 payments
  6. Cardiovascular Systems Inc. $256 2 payments
  7. Medtronic, Inc. $228 3 payments
  8. CVRx, Inc. $224 4 payments
  9. Boston Scientific Corporation $217 7 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $203 6 payments
  11. Other $1,774 73 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,385 270 payments
  2. Travel and Lodging $189 10 payments
  3. Education $99 1 payment
Products named General payments · program years 2019–2025
  1. Impella $1,127 30 payments
  2. Repatha $842 57 payments
  3. VERQUVO $445 29 payments
  4. Diamondback Peripheral $256 2 payments
  5. Diamondback Coronary $256 2 payments
  6. LEQVIO $236 15 payments
  7. Barostim Neo System $224 4 payments
  8. FARXIGA $199 14 payments
  9. ENTRESTO $187 12 payments
  10. OPSUMIT $173 5 payments
  11. Other $2,936 127 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 54 drugs

Part D claims

5,387

Median for Cardiology: 2,533

Drug cost

$1,111,215

Median for Cardiology: $485,213

Branded share of claims

29.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 307 $325,417
Repatha Sureclick Evolocumab Brand 245 $223,391
Brilinta Ticagrelor Brand 306 $198,886
Entresto Sacubitril/Valsartan Brand 94 $92,562
Xarelto Rivaroxaban Brand 62 $69,073
Praluent Pen Alirocumab Brand 84 $64,481
Farxiga Dapagliflozin Propanediol Brand 25 $26,892
Jardiance Empagliflozin Brand 19 $18,783
Rosuvastatin Calcium Generic 608 $11,966
Icosapent Ethyl Generic 21 $7,277

The 10 drugs with the highest cost, of 54 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$312,744

Of which drugs: $127

Medicare patients

924

Average age 77

Services billed

4,763

470 women, 454 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 71%
Arthritis 57%
Heart failure 49%
Diabetes 47%
Atrial fibrillation 42%
Chronic kidney disease 42%
Depression 34%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, aminophyllin, up to 250 mg J0280 Office 22 22 $119
Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) J0153 Office 22 22 $9

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $159
$159 19 —
Repatha
  • Amgen Inc. $113
$113 245 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $79
$79 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $67
$67 — —
ELIQUIS
  • PFIZER INC. $32
  • E.R. Squibb & Sons, L.L.C. $16
$47 307 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

281 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record